Based in Otsuka’s US head office in Princeton, Armin is part of Otsuka’s scouting & evaluation team, charged with identifying, evaluating and bringing into Otsuka’s global development pipeline new innovative drugs that address serious medical needs one of Otsuka’s two areas of strategic interest, (a) neuroscience, including psychiatry and neurology, and (b) specialty pharma, particularly rare kidney, autoimmune diseases and inborn errors of metabolism.
Armin obtained his M.S. from the University of Stuttgart and his Ph.D. in molecular & cellular biology from the University of Tokyo. He has been involved in many of Otsuka’s deals, including the acquisition of Jnana Therapeutics and a recent equity investment in Sonothera.
